About ASTThe American Society of Transplantation was established in 1982 and is an organization of more than 2,700 transplant professionals dedicated to improving patient care by promoting research, education, advocacy and organ donation. AST provides a forum for the exchange of knowledge, scientific information and expertise in the field of transplantation.
‘.. Through a variety of measures – the speed and duration of response to treatment, change in tumor size, and the proportion of patients alive and shows no signs of progressive disease – the group that has selumetinib much better than the other group. Most clinically significant were the improved speed of response to treatment and prolonged progression-free survival . Although the in the in the group selumetinib longer on average than in the placebo group – 9.4 months compared to 5.2 months – the improvement was not statistically significant.Association Awards $ 1.5 Million Grant In order to Acceleron ACE-031 support for.
Acceleron Pharma, a biopharmaceutical company developing novel therapeutics that of modulating cell growth and tissues, including muscle, bone, red cells and vascular system of has announced that it is has a $ 1,000 grant from the muscular Dystrophy Association on clinical studies with ACE-031 into Duchenne , a debilitating neuromuscular disease in patients will experience assist a progressive loss of muscle size and strength bestowed. ACE-031 is an investigational medicinal protein therapeutic develops to gain muscle and increase the strength by the blocking protein to muscle growth muscle growth and strength..